OUR PHILOSOPHY
At Jabez, we Are developing a smarter model for cancer therapy.
At the core of Jabez’s strategy is a therapeutic framework we call 3-C Therapeutics – cancer treatments that are:

Convenient
Orally available, low-toxicity, outpatient-compatible to maximize compliance.

Cost-Effective
Scalable synthesis, efficient manufacturing, global potential

Cooperative (Synergistic)
Rationally synergistic with standard-of-care treatments
Clinical Partners:



OUR STRATEGIC VISION
Jabez Is More Than A Small Molecule Company
Our strategy balances short-term clinical progress with a long-term asset acquisition and development engine grounded in the 3-C model.

Advance Our Lead Program
Establish safety, expand to synergistic indications (e.g., AML, MM), and demonstrate proof-of-concept for the Jabez model.

Demonstrate 3-C Clinical Impact
We aim to show that 3-C therapeutics can drive real-world outcomes—improving efficacy without added toxicity or logistical burden.

Expand Our Portfolio
We will identify and license additional assets that fit our 3-C filter to build a pipeline of smart, synergistic therapeutics.

Scale the Jabez Model
With each successful program, we expand our ability to systematically evaluate, acquire, and deploy high-impact therapies.
CLINICAL DEVELOPMENT
Our Clinical Trials
Jabez Biosciences is proud to be a clinical-stage biotechnology company. We are currently enrolling patients in a Phase 1 clinical trial evaluating our lead candidate in advanced solid tumors and non-Hodgkin lymphoma.
Latest
News & Events
- 05.09.25
- News
Jabez Biosciences, Inc. Announced Phase 1 Clinical Trial of JBZ-001 at AACR 2025
- 04.03.25
- News
Jabez Biosciences, Inc. Announces First Patient Dosed in Phase 1 Oncology Clinical Study of JBZ-001
Jabez Biosciences is developing a smarter model for cancer therapy.
Social Media

Jabez Biosciences. 2025. All Rights Reserved. Website made by Flyte Bio.